FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2068100145> ?p ?o ?g. }

• W2068100145 endingPage "282" @default.
• W2068100145 startingPage "276" @default.
• W2068100145 abstract "Abstract BACKGROUND: Level I evidence indicates that neoadjuvant cisplatin‐based chemotherapy, in combination with radical cystectomy (RC), is associated with a significant survival advantage for patients with muscle‐invasive bladder cancer. Despite this, neoadjuvant chemotherapy is not uniformly used. Our objective was to determine the patterns of utilization of neoadjuvant chemotherapy in patients undergoing RC for muscle invasive bladder cancer in a contemporary cohort in a tertiary care center. METHODS: A retrospective review was performed of patients with bladder cancer who underwent RC between 2003 and 2008 at our institution. Clinical stage, pathologic stage, renal function, and perioperative chemotherapy treatments were tabulated. Primary outcome measures were the type and use of neoadjuvant chemotherapy among eligible patients. Secondary measures were the utilization patterns of adjuvant chemotherapy, renal function, pathologic outcomes, and disease specific and overall survival. Reasons for nonutilization of chemotherapy were also examined. RESULTS: Among 238 patients who underwent RC for bladder cancer, 145 had a preoperative clinical stage ≥T2. Only 17% (25 of 145) of these patients received cisplatin‐based neoadjuvant chemotherapy. The renal function was adequate (CrCl > 60 ml/min) in 97 (67%) of these patients. Patients who received neoadjuvant chemotherapy had higher p0 rates (29% vs 8%) than patients who did not receive neoadjuvant therapy. Advanced patient age, comorbidities, concerns over toxicity of chemotherapy, and the modest nature of benefit from neoadjuvant chemotherapy may explain why this treatment is not often used. CONCLUSIONS: Despite level I evidence, neoadjuvant cisplatin‐based chemotherapies continue to be underutilized in the management of bladder cancer, even at a high‐volume tertiary center. A prospective evaluation of management choices, including the patient and physician factors involved in the use of perioperative cisplatin‐based chemotherapy in bladder cancer, is indicated. Cancer 2011. © 2010 American Cancer Society." @default.
• W2068100145 created "2016-06-24" @default.
• W2068100145 creator A5018387825 @default.
• W2068100145 creator A5041923034 @default.
• W2068100145 creator A5051588739 @default.
• W2068100145 creator A5053069471 @default.
• W2068100145 creator A5063056787 @default.
• W2068100145 creator A5081652574 @default.
• W2068100145 creator A5086493388 @default.
• W2068100145 date "2010-09-09" @default.
• W2068100145 modified "2023-10-18" @default.
• W2068100145 title "Contemporary use of perioperative cisplatin-based chemotherapy in patients with muscle-invasive bladder cancer" @default.
• W2068100145 cites W1896260571 @default.
• W2068100145 cites W1971903914 @default.
• W2068100145 cites W1975316159 @default.
• W2068100145 cites W1975918912 @default.
• W2068100145 cites W1986382801 @default.
• W2068100145 cites W1998580221 @default.
• W2068100145 cites W2008523684 @default.
• W2068100145 cites W2014279888 @default.
• W2068100145 cites W2034161521 @default.
• W2068100145 cites W2041435757 @default.
• W2068100145 cites W2072486397 @default.
• W2068100145 cites W2084075250 @default.
• W2068100145 cites W2105935489 @default.
• W2068100145 cites W2121607722 @default.
• W2068100145 cites W2126069168 @default.
• W2068100145 cites W2128042367 @default.
• W2068100145 cites W2141414146 @default.
• W2068100145 cites W2150748627 @default.
• W2068100145 cites W2157656755 @default.
• W2068100145 cites W2166453367 @default.
• W2068100145 cites W2166901993 @default.
• W2068100145 cites W2168558330 @default.
• W2068100145 cites W2168846224 @default.
• W2068100145 cites W2338389744 @default.
• W2068100145 cites W2470654889 @default.
• W2068100145 cites W4376546343 @default.
• W2068100145 doi "https://doi.org/10.1002/cncr.25429" @default.
• W2068100145 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20830767" @default.
• W2068100145 hasPublicationYear "2010" @default.
• W2068100145 type Work @default.
• W2068100145 sameAs 2068100145 @default.
• W2068100145 citedByCount "130" @default.
• W2068100145 countsByYear W20681001452012 @default.
• W2068100145 countsByYear W20681001452013 @default.
• W2068100145 countsByYear W20681001452014 @default.
• W2068100145 countsByYear W20681001452015 @default.
• W2068100145 countsByYear W20681001452016 @default.
• W2068100145 countsByYear W20681001452017 @default.
• W2068100145 countsByYear W20681001452018 @default.
• W2068100145 countsByYear W20681001452019 @default.
• W2068100145 countsByYear W20681001452020 @default.
• W2068100145 countsByYear W20681001452021 @default.
• W2068100145 countsByYear W20681001452022 @default.
• W2068100145 countsByYear W20681001452023 @default.
• W2068100145 crossrefType "journal-article" @default.
• W2068100145 hasAuthorship W2068100145A5018387825 @default.
• W2068100145 hasAuthorship W2068100145A5041923034 @default.
• W2068100145 hasAuthorship W2068100145A5051588739 @default.
• W2068100145 hasAuthorship W2068100145A5053069471 @default.
• W2068100145 hasAuthorship W2068100145A5063056787 @default.
• W2068100145 hasAuthorship W2068100145A5081652574 @default.
• W2068100145 hasAuthorship W2068100145A5086493388 @default.
• W2068100145 hasBestOaLocation W20681001451 @default.
• W2068100145 hasConcept C121608353 @default.
• W2068100145 hasConcept C126322002 @default.
• W2068100145 hasConcept C126894567 @default.
• W2068100145 hasConcept C141071460 @default.
• W2068100145 hasConcept C143998085 @default.
• W2068100145 hasConcept C2775910329 @default.
• W2068100145 hasConcept C2776694085 @default.
• W2068100145 hasConcept C2778239845 @default.
• W2068100145 hasConcept C2778292576 @default.
• W2068100145 hasConcept C2780352672 @default.
• W2068100145 hasConcept C31174226 @default.
• W2068100145 hasConcept C530470458 @default.
• W2068100145 hasConcept C71924100 @default.
• W2068100145 hasConceptScore W2068100145C121608353 @default.
• W2068100145 hasConceptScore W2068100145C126322002 @default.
• W2068100145 hasConceptScore W2068100145C126894567 @default.
• W2068100145 hasConceptScore W2068100145C141071460 @default.
• W2068100145 hasConceptScore W2068100145C143998085 @default.
• W2068100145 hasConceptScore W2068100145C2775910329 @default.
• W2068100145 hasConceptScore W2068100145C2776694085 @default.
• W2068100145 hasConceptScore W2068100145C2778239845 @default.
• W2068100145 hasConceptScore W2068100145C2778292576 @default.
• W2068100145 hasConceptScore W2068100145C2780352672 @default.
• W2068100145 hasConceptScore W2068100145C31174226 @default.
• W2068100145 hasConceptScore W2068100145C530470458 @default.
• W2068100145 hasConceptScore W2068100145C71924100 @default.
• W2068100145 hasIssue "2" @default.
• W2068100145 hasLocation W20681001451 @default.
• W2068100145 hasLocation W20681001452 @default.
• W2068100145 hasOpenAccess W2068100145 @default.
• W2068100145 hasPrimaryLocation W20681001451 @default.
• W2068100145 hasRelatedWork W2109785281 @default.
• W2068100145 hasRelatedWork W2189722039 @default.

• next